ClinicalTrials.gg
Active, not recruitingNCT05664737Updated Sep 10, 2026

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia

A Phase 2 interventional study of Luspatercept and Placebo in Anemia, sponsored by Bristol-Myers Squibb. Active, not recruiting at 31 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing luspatercept in Anemia — 6 open to participants now, 13 under way, 4 of them phase 3. luspatercept · Anemia.

Planned enrollment
6th of 19
189 · median 85
Started
2022
with 2 others
Phase 2
10 of 19
4 open now
Primary completion
2027-07
later than 8 of 12 live
Registered
10th of 19
by date
Lead sponsor
4 of 19
Bristol-Myers Squibb

Among the 19 studies testing luspatercept in Anemia, this one is the 6th largest by planned enrollment, is one of 3 that started in 2022, is one of 10 in phase 2, reaches primary completion later than 8 of the 12 other live ones, and was the 10th registered.

Anemia

1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.

Browse Anemia studies →

Open to participants now

6 of the 19 studies testing luspatercept in Anemia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About luspatercept

luspatercept: first FDA approval 2019 (REBLOZYL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing luspatercept in Anemia, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in adult participants with α-thalassemia hemoglobin H (HbH) disease and determine the safety and drug levels in adolescent participants.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Luspatercept
  • BMS-986346
  • ACE-536
  • α-thalassemia
  • Alpha Thalassemia
  • Reblozyl
  • Transfusions
  • Non-transfusion dependent
  • RBC transfusion dependent
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participant≥ 18 years with documented diagnosis of A-Thal HbH disease with Transfusion dependence defined as:.

    i) TD participant: ≥ 6 RBC units during the 24 weeks prior to randomization. ii) NTD participant:\< 6 RBC units during the 24 weeks prior to randomization(transfusion due to conditions other than A-Thal will not be considered)and, RBC transfusion-free during at least 8 weeks prior to randomization(unless transfusion was required to treat an acute medical condition other than A-Thal) and, mean baseline ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to randomization; hemoglobin values within 21 days post-transfusion will be excluded.

  • Adult participant has (ECOG) 34 score of 0 or 1.
  • Adolescent participant 12 years to \< 18 years with documented diagnosis of A-Thal HbH disease with transfusion dependence defined as:.

    i) TD participant: ≥ 4 RBC events during the 24 weeks prior to enrollment and, no transfusion-free period for > 56 days during the 24 weeks prior to enrollment. Participants must have a history of regular transfusions for at least 2 years.

ii) NTD participant:\< 4 RBC events during the 24 weeks prior to enrollment and RBC transfusion-free during at least 8 weeks prior to enrollment and, mean baseline Hb ≤ 10 g/dL, based on a minimum of 2 measurements ≥ 1 week apart within 4 weeks prior to enrollment, hemoglobin values within 21 days post-transfusion will be excluded.

iii) Participant has (age ≥16 years) or Lansky (age \< 16 years) performance status score ≥ 50 at screening.

Exclusion criteria

Exclusion Criteria:

  • Medical Conditions: Diagnosis of A-ThalTrait, Bart hydrops, ATRx A-Thal, hemoglobin S/β-thalassemia, myelodysplasia subtype anemia, or with HbE homozygous beta gene mutation. Anemia related to nutritional deficiency, anemia of chronic disease, hemolytic anemia, or any other hemolytic anemias. Undergone episodes of hemolysis not related to A-Thal within the 8 weeks prior to randomization. Applicable for the EU only: Bleeding disorders manifested by frequent bleeding episodes (eg, menorrhagia, epistaxis, clotting disorders).
  • Participant has deep vein thrombosis (DVT), stroke or other thromboembolic event(s) (except clogged indwelling catheter) requiring medical intervention ≤ 24weeks prior to randomization.
  • Participant has uncontrolled hypertension. Controlled hypertension for this protocol is considered: blood pressure value corresponding to ≤Grade 1 according to Version 5.0. with or without pharmacological treatment.
  • Reproductive Status: Women who are pregnant, plan to get pregnant during the study, or who are breastfeeding.
  • Prior/Concomitant: Undergone HSCTs or gene therapy (candidates for or gene therapy with waiting period of ≥ 12 months are eligible).
  • Use of hydroxyurea treatment ≤ 12 weeks prior to enrollment for NTD participants and ≤ 24 weeks for TD participants.
  • Participant who has extramedullary hematopoiesis (EMH) complications requiring treatment to control the growth of EMH mass(es) during the screening period.
  • Any medical or psychiatric condition (including active infections, recent surgery, sequelae of diseases or interventions, laboratory abnormalities or concurrent treatment) that in the opinion of the investigator would put the participant at unacceptable risk of participating in the study or that could affect interpretability of data.
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
189 participants (estimated)

Study arms

  • Experimental
    Transfusion Dependent (TD): Luspatercept + Best supportive care (BSC)

    Biological: Luspatercept

  • Placebo comparator
    Adult TD Cohort: Placebo + BSC

    Drug: Placebo

  • Experimental
    Non-transfusion Dependent (NTD): Luspatercept + BSC

    Biological: Luspatercept

  • Placebo comparator
    Adult NTD Cohort: Placebo + BSC

    Drug: Placebo

Interventions

  • BiologicalLuspatercept

    Specified dose on specified days

    Also known as: BMS-986346, ACE-536, REBLOZYL

  • DrugPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units during any continuous 12 weeks during Week 13-48 compared to 12-week interval immediately prior to date of first dose

    Adult TD Cohort

    Time frame: Up to Week 48

  2. Number of participants with an increase from baseline of ≥ 1.0 grams (g)/decilitre (dL) in mean hemoglobin (Hb) values over the continuous 12-week interval from Week 13 to Week 24 in the absence of RBC transfusion

    Adult NTD Cohort

    Time frame: Up to Week 24

  3. Dose-limiting toxicities (DLTs) defined as observance of ≥ Grade 3-related hemolytic crises or ≥ Grade 3-related event outside of the known safety profile occurring within the 21 days from their first dose of study therapy

    Adolescent TD and NTD Cohorts

    Time frame: Up to Week 3

  4. Number of participants with adverse events (AEs)

    Adolescent TD and NTD Cohorts

    Time frame: Up to 5 years

  5. Pharmacokinetics (PK): Serum concentration of Luspatercept

    Adolescent TD and NTD Cohorts

    Time frame: Up to Week 108

Secondary outcomes

  1. Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units during any continuous 24-week interval on treatment compared to 24-week interval immediately prior to date of first dose

    Adult TD Cohort

    Time frame: Up to Week 108

  2. The longest duration with ≥ 50% reduction from baseline in RBC transfusion burden with a reduction of at least 2 units

    Adult TD Cohort

    Time frame: Up to Week 108

  3. Number of RBC transfusion units from week 1 to week 48

    Adult and Adolescent TD Cohorts

    Time frame: Up to Week 48

  4. Change from baseline in hemoglobin in the absence of transfusion at Week 24

    Adult and Adolescent NTD Cohorts

    Time frame: Up to Week 24

  5. The longest duration of an increase from baseline of ≥ 1.0 g/dL in mean hemoglobin values starting from Week 13 in the absence of transfusion

    Adult NTD Cohort

    Time frame: Up to Week 108

  6. Time Duration with an increase from baseline of ≥ 1.0 g/dL in hemoglobin values in the absence of transfusion within 48 weeks

    Adult NTD Cohort

    Time frame: Up to Week 48

  7. Number of participants with an increase from baseline of ≥1.0 g/dL in mean Hb values over the continuous 12- week interval in the absence of transfusion

    Adult NTD Cohort

    Time frame: Up to Week 24

  8. ≥ 3 Increase from Baseline in Functional Assessment of Cancer Therapy Anemia Fatigue Subscale (FACT-An FS) Score from Baseline to the period from Week 13 to Week 24

    Adult NTD Cohort

    Time frame: Up to Week 24

  9. Number of participants with AEs

    Adult and Adolescent TD and NTD Cohorts

    Time frame: Up to 5 years

  10. Number of participants with laboratory abnormalities

    Adult TD and NTD Cohorts

    Time frame: Up to 5 Years

  11. Number of participants with immunogenicity

    Adult TD and NTD Cohorts

    Time frame: Up to 2 Years

  12. Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden during any continuous 24-week interval within 48 weeks compared to the 24-week interval immediately prior to the date of first dose

    Adult TD Cohort

    Time frame: Up to Week 48

  13. Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden during any continuous 12-week interval compared to the 12-week interval immediately prior to the date of first dose

    Adult TD Cohort

    Time frame: Up to Week 108

  14. Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden from Week 13 to Week 24 and Week 37 to Week 48 compared to the 12-week interval immediately prior to the date of first dose

    Adult TD Cohort

    Time frame: Up to Week 48

  15. Number of participants with ≥ 33% reduction from baseline in RBC transfusion burden from Week 1 to Week 24 and Week 25 to Week 48 compared to the 24-week interval immediately prior to the date of first dose

    Adult TD Cohort

    Time frame: Up to Week 48

  16. Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden from Week 13 to Week 24 and Week 37 to Week 48 compared to the 12-week interval immediately prior to the date of first dose

    Adult TD Cohort

    Time frame: Up to Week 48

  17. Number of participants with ≥ 50% reduction from baseline in RBC transfusion burden from Week 1 to Week 24 and Week 25 to Week 48 compared to the 24-week interval immediately prior to the date of first dose

    Adult TD Cohort

    Time frame: Up to Week 48

  18. Change from baseline in total RBC units transfused from Week 1 to Week 24, Week 25 to Week 48, and Week 1 to Week 48

    Adult TD Cohort

    Time frame: Up to Week 48

  19. The longest duration of RBC transfusion-free period for participants who achieve transfusion-free period of ≥ 12 weeks

    Adult TD Cohort

    Time frame: Up to Week 108

  20. The longest duration of reduction in transfusion burden for participants who achieve a response (rolling 12-week and 24-week response, both for ≥ 33% and ≥ 50% reduction)

    Adult TD Cohort

    Time frame: Up to Week 108

  21. Time from first dose to first day of response (rolling 12-week and 24-week response, both for ≥ 33% and ≥ 50% reduction)

    Adult TD Cohort

    Time frame: Up to Week 108

  22. Change from baseline in number of transfusion events at Week 48

    Adult TD Cohort

    Time frame: Up to Week 48

  23. Number of participants who achieve RBC transfusion-free period of any continuous ≥ 12 weeks during treatment

    Adult and Adolescent TD and NTD Cohorts

    Time frame: Up to Week 108

  24. Number of participants who achieve RBC transfusion-free period of any continuous ≥ 24 weeks during treatment

    Adult and Adolescent TD and NTD Cohorts

    Time frame: Up to Week 108

  25. Time to first transfusion

    Adult and Adolescent NTD Cohorts

    Time frame: Up to Week 108

  26. Number of transfusions

    Adult NTD Cohort

    Time frame: Within 48 Weeks

  27. Number of transfusion visits/units

    Adult NTD Cohort

    Time frame: Within 48 Weeks

  28. Change from baseline in mean hemoglobin values over the continuous 12-week interval from Week 13 to Week 24 and Week 37 to Week 48 in the absence of transfusions

    Adult TD and NTD Cohorts

    Time frame: Up to Week 48

  29. Number of participants achieving an increase from baseline of ≥1.0g/dL or ≥1.5g/dL in mean Hb values in absence of transfusions from Week 13 to Week 24, Week 37 to Week 48 and during any continuous 12-week window within 24 weeks and 48 weeks

    Adult NTD Cohort

    Time frame: Up to Week 48

  30. Time from first to last Hb measurement with increase from baseline by ≥ 1.0 g/dL

    Adult NTD Cohorts

    Time frame: Up to Week 108

  31. Time to the first increase from baseline of ≥ 1.0 g/dL in mean Hb value

    Adolescent NTD Cohort

    Time frame: Up to Week 48

  32. Number of participants who achieve an increase in mean Hb of >10g/dL values during any continuous 12-week and 24-week interval within 48 weeks in the absence of transfusions

    Adult NTD Cohort

    Time frame: Up to Week 48

  33. Change from baseline in self-reported health-related quality of life (HRQoL) assessed by physical component summary (PCS) and mental component summary (MCS) of 36-item short-form health survey version2 (SF-36v2) at Week 24 and Week 48

    Adult TD and NTD Cohorts

    Time frame: Up to Week 48

  34. Change from baseline in non-transfusion dependent β-thalassemia patient-reported outcome (NTDT-PRO) Tiredness/weakness (T/W) and shortness of breath (SoB) domain scores from Week 13 to Week 24 and from Week 37 to Week 48

    Adult NTD Cohort

    Time frame: Up to Week 48

  35. Change from baseline in FACT-An FS Score at Week 24 and Week 48

    Adult NTD Cohort

    Time frame: Up to Week 48

  36. Change from baseline in Functional Assessment of Cancer Therapy Anemia Anemia Subscale (FACT-An AS) at Week 24 and Week 48

    Adult NTD Cohort

    Time frame: Up to Week 48

  37. Number of participants with at least one hemolytic crisis

    Adult TD and NTD Cohorts

    Time frame: Up to Week 108

  38. Rate of hemolytic crises

    Adult TD and NTD Cohorts

    Time frame: Up to Week 108

  39. Time to first hemolytic crisis

    Adult TD and NTD Cohorts

    Time frame: Up to Week 108

  40. Time to second hemolytic crisis

    Adult TD and NTD Cohorts

    Time frame: Up to Week 108

  41. Change from baseline in hemolysis markers at Week 24 and Week 48

    Adult TD and NTD Cohorts:

    Time frame: Up to Week 48

  42. Change from baseline in the 6-minute walk test (6MWT) distance at Week 24 and Week 48

    Adult NTD Cohort

    Time frame: Up to Week 48

  43. Pharmacokinetics (PK): Serum concentration of Luspatercept

    Adult and Adolescent TD and NTD Cohorts

    Time frame: Up to Week 108

  44. Percent Change from Baseline in Biomarkers for Erythropoiesis at Week 48

    Adult and Adolescent TD and NTD Cohorts. The biomarkers for erythropoiesis to be evaluated include sTfR1, erythropoietin (EPO), growth differentiation factor (GDF11), GDF8, GDF15. The change will be measured as a percentage of change from baseline for all the biomarkers.

    Time frame: Baseline, Week 48

  45. Percent Change from Baseline in Biomarkers and Parameters for Iron Homeostasis at Week 48

    Adult TD and NTD Cohorts. The biomarkers and parameters for iron homeostasis to be evaluated include hepcidin, erythroferrone (ERFE), serum ferritin, liver iron concentration (LIC), myocardial iron, iron chelation therapy (ICT). The change will be measured as a percentage of change from baseline for all the biomarkers.

    Time frame: Up to 5 Years

  46. Percent Change from Baseline in HB Variants including HBH

    Adult TD and NTD Cohorts.

    Time frame: Baseline, Week 48

  47. Change in mean corpuscular volume (MCV) at Week 48

    Adult TD and NTD Cohorts

    Time frame: Baseline, Week 48

  48. Change in mean corpuscular hemoglobin (MCH) at Week 48

    Adult TD and NTD Cohorts

    Time frame: Baseline, Week 48

  49. Change in nucleated red blood cells (nRBC) at Week 48

    Adult TD and NTD Cohorts

    Time frame: Baseline, Week 48

  50. Change in red blood cells (RBC) at Week 48

    Adult TD and NTD Cohorts

    Time frame: Baseline, Week 48

  51. The longest duration with reduction from baseline in the RBC transfusion burden

    Adolescent TD Cohort

    Time frame: Up to Week 48

  52. The number of participants with ≥ 50% reduction from baseline in RBC transfusion burden during an continuous 12 weeks during Weeks 13-48

    Adolescent TD Cohort

    Time frame: Up to Week 48

  53. The number of participants with ≥ 33% reduction from baseline in RBC transfusion burden during an continuous 24 weeks

    Adolescent TD Cohort

    Time frame: Up to Week 48

  54. Number of participants achieving an increase from baseline of ≥1.0g/dL in mean Hb values in absence of transfusions from Week 13 to Week 24

    Adolescent NTD Cohort

    Time frame: Up to Week 24

  55. Cumulative time (in weeks) with an increase from baseline of ≥1.0g/dL in mean Hb values in absence of RBC transfusions within 48 weeks

    Adolescent NTD Cohort

    Time frame: Up to Week 48

  56. Number of participants who achieve an increase in mean Hb of >10g/dL values during any continuous 12-week interval during week 13 to week 48 in the absence of transfusions

    Adolescent NTD Cohort

    Time frame: Up to Week 48

  57. The longest duration with an increase from baseline of ≥1.0g/dL in mean Hb values in absence of transfusions

    Adolescent NTD Cohort

    Time frame: Up to Week 48

  58. Number of participants with antidrug antibody (ADA)

    Adolescent TD and NTD Cohorts

    Time frame: Up to 2 Years

  59. Mean change in biomarkers for hemolysis

    Adolescent TD and NTD Cohorts. Biomarkers for hemolysis to be evaluated include total/direct/indirect bilirubin, serum lactate dehydrogenase (sLDH), haptoglobin, reticulocytes and nucleated red blood cells, reticulocyte production index (RPI), and urinary urobilinogen

    Time frame: Up to Week 48

  60. Mean change in biomarkers and parameters for iron homeostasis

    Adolescent TD and NTD Cohorts. The biomarkers and parameters for iron homeostasis to be evaluated include serum ferritin, liver and myocardial iron content (LIC), (MIC), iron chelation therapy (ICT).

    Time frame: Up to 5 Years

  61. Assessment of Hematologic Parameters

    Adolescent TD and NTD Cohorts. The hematologic assessments to be evaluated are red blood cell (RBC) count, hemoglobin, hematocrit, reticulocyte count, nucleated red blood cell count, platelet, leukocyte and neutrophile counts, RBC indices, RBC morphology, and Hb variants.

    Time frame: Up to Week 48

  62. The change from baseline in the number of health care resource utilization (HCRU)

    Adolescent TD and NTD Cohorts

    Time frame: Up to 5 Years

  63. Mean change from baseline in Pediatric Quality of Life Inventory (PedsQL) domain scores

    Adolescent TD and NTD Cohorts

    Time frame: Up to 3 Years

  64. Mean change from baseline EQ-5D-5L utility index

    Adolescent TD and NTD Cohorts

    Time frame: Up to 3 Years

  65. Mean change from baseline visual analogue scale (VAS) scores

    Adolescent TD and NTD Cohorts

    Time frame: Up to 3 Years

07

Study locations

31 sites
  • Local Institution - 0029
    Guangzhou, GD 510120, China
  • Local Institution - 0015
    Guangzhou, GD 510515, China
  • Local Institution - 0013
    Foshan, Guangdong 528000, China
  • Local Institution - 0017
    Maoming Shi, Guangdong 525000, China
  • Local Institution - 0030
    Shenzhen Shi, Guangdong 518025, China
  • Local Institution - 0023
    Liuzhou, Guangxi 545006, China
  • Local Institution - 0014
    Nanning, GX 530021, China
  • Local Institution - 0011
    Haikou, Hainan 570203, China
  • Local Institution - 0012
    Kunming, Yunnan 650032, China
  • Local Institution - 0002
    Haikou, 570311, China
  • Local Institution - 0016
    Nanning, 530021, China
  • Local Institution - 0018
    Rio, G 265 04, Greece
  • Local Institution - 0006
    Athens, 115 27, Greece
  • Local Institution - 0009
    Goudi, 11527, Greece
  • Local Institution - 0007
    Larissa, 26504, Greece
  • Local Institution - 0025
    Hong Kong, HK, Hong Kong
  • Local Institution - 0026
    Genova, GE 16128, Italy
  • Local Institution - 0020
    Orbassano, TO 10043, Italy
  • Local Institution - 0028
    Naples, 80131, Italy
  • Local Institution - 0019
    Naples, 80138, Italy
  • Local Institution - 0032
    Kuala Lumpur, WP 50586, Malaysia
  • Local Institution - 0033
    Johor Bahru, 80100, Malaysia
  • Local Institution - 0034
    Riyadh, 11411, Saudi Arabia
  • Local Institution - 0036
    Singapore, 229899, Singapore
  • Local Institution - 0010
    Kaohsiung City, KHH 807, Taiwan
  • Local Institution - 0004
    Nan Gang Qu, TPE 10002, Taiwan
  • Local Institution - 0003
    Taichung, TXG 40447, Taiwan
  • Local Institution - 0001
    Bangkok Noi, Bangkok 10700, Thailand
  • Local Institution - 0031
    Mueang Phitsanulok, 65000, Thailand
  • Local Institution - 0027
    Altındağ, 06230, Turkey (Türkiye)
  • Local Institution - 0021
    Topkapı, 34093, Turkey (Türkiye)
08

References and documents

Publications

  • Diamantidis MD, Pitsava S, Zayed O, Argyrakouli I, Karapiperis K, Chatzoulis C, Alexiou E, Manafas A, Tsangalas E, Karakoussis K. Concomitant Presence of Hb Agrinio and - -Med Deletion in a Greek Male Patient with Hemoglobinopathy H: More Severe Phenotype and Literature Review. Hematol Rep. 2023 Aug 8;15(3):483-490. doi: 10.3390/hematolrep15030050. PubMed 37606495 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Jul 2027, 55 months after the start.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's planned 55 months is above that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2022
First posted
Dec 27, 2022
StartActual
Dec 9, 2022
Primary completionEst.
Jul 16, 2027
CompletionEst.
Aug 14, 2034
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05664737
Responsible party
Sponsor
First posted
Dec 27, 2022
Start date
Dec 9, 2022
Primary completion
Jul 16, 2027 (estimated)
Completion
Aug 14, 2034 (estimated)
Last update
Sep 10, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luspatercept

Start the discussion